Cheolhee Won
Overview
Explore the profile of Cheolhee Won including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
454
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shin H, Kang S, Won C, Min D
Adv Sci (Weinh)
. 2024 Jul;
11(35):e2404590.
PMID: 39010673
Recently, lipid nanoparticles (LNPs)-based mRNA delivery has been approved by the FDA for SARS-CoV-2 vaccines. However, there are still considerable points for improvement in LNPs. Especially, local administration of LNPs-formulated...
2.
Shin H, Kang S, Won C, Min D
ACS Nano
. 2023 Aug;
17(17):17554-17567.
PMID: 37643221
Localized expression of immunomodulatory molecules can stimulate immune responses against tumors in the tumor microenvironment while avoiding toxicities associated with systemic administration. In this study, we developed a polyethylenimine-modified porous...
3.
Shin H, Kang S, Chae S, Won C, Min D
ACS Appl Mater Interfaces
. 2023 Mar;
PMID: 36913611
Cancer vaccine is one of the immunotherapeutic strategies aiming to effectively deliver cancer antigens to professional antigen-presenting cells such as dendritic cells (DCs), macrophages, and B cells to elicit a...
4.
Park I, Kim S, Yim Y, Park G, Choi J, Won C, et al.
Nat Commun
. 2022 Aug;
13(1):4568.
PMID: 35931667
Artificial, synthetic chaperones have attracted much attention in biomedical research due to their ability to control the folding of proteins and peptides. Here, we report bio-inspired multifunctional porous nanoparticles to...
5.
Kim J, Kang S, Kim K, Heo M, Park D, Lee J, et al.
Biomaterials
. 2021 Nov;
280:121257.
PMID: 34839122
Recent strategies in cancer immunotherapy based on interleukin-2 (IL-2) are generally focused on reducing regulatory T cell (Treg) development by modifying IL-2 receptor alpha (IL-2Rα) domain. However, the clinical utility...
6.
Park S, Shin H, Won C, Min D
Nanomedicine
. 2020 Oct;
32:102316.
PMID: 33068744
Among various strategies to treat neurodegenerative disorders, cell replacement therapies have drawn much attention recently. Such a trend led to the increase in demand for the rare and specialized cells,...
7.
Park S, Kim J, Kang S, Cha H, Shin H, Park J, et al.
Sci Adv
. 2020 Jun;
6(22):eaaz8201.
PMID: 32523995
Direct-acting agents against viral components are considered as the most promising candidates for the successful antiviral therapeutics. To date, no direct-acting drugs exist for the treatment against dengue virus (DV)...
8.
Kang S, Kim J, Ahn M, Kim J, Heo M, Min D, et al.
Nanoscale
. 2020 Mar;
12(11):6385-6393.
PMID: 32134425
Skin fibrosis occurs in a variety of human diseases but the current anti-fibrosis treatments are not sufficient. One major cause of fibrotic diseases shared across diverse organ fibrosis is uncontrolled...
9.
Ryoo S, Yim Y, Kim Y, Park I, Na H, Lee J, et al.
Sci Rep
. 2018 Aug;
8(1):11413.
PMID: 30061704
MicroRNAs (miRNAs) are important regulatory RNAs that control gene expression in various biological processes. Therefore, control over the disease-related miRNA expression is important both for basic research and for a...
10.
Park S, Kim S, Kim S, Jeon N, Song J, Won C, et al.
ACS Appl Mater Interfaces
. 2017 Sep;
9(40):34634-34640.
PMID: 28921950
An improved cell conversion strategy for neural differentiation of mouse embryonic stem (mES) cells is developed by incorporating functionalized mesoporous silica nanoparticle (MSN) as an efficient delivery carrier of retinoic...